Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Mitochondrial Membranes

Mitochondrial Membranes

A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Implementing a Curricular Model for Structured Reflection in a Neurology Clinical Clerkship.

Journal of medical education and curricular development·2025

Same author

[High expression of SURF4 promotes migration, invasion and proliferation of gastric cancer cells by inhibiting tight junction proteins].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2025

Same author

Fibrinogen-albumin-ratio is an independent predictor of deep vein thrombosis in patients undergoing knee arthroplasty.

Journal of orthopaedics·2025

Same author

Protamine-Facilitated Same-Day Discharge Following Distal Transradial Angiography.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025

Same author

Targeted Inhibition of cGAS/STING signaling induced by aberrant R-Loops in the nucleus pulposus to alleviate cellular senescence and intervertebral disc degeneration.

Journal of nanobiotechnology·2025

Same author

Immune Dysregulation and Hub Gene Identification in Non-Pulmonary Sepsis-Induced Acute Lung Injury: Insights from Transcriptomic and Experimental Analyses.

Current medical science·2025

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Published on: January 24, 2017

Modulating mitochondrial dynamics in CMT2A: a multifaceted platform for drug discovery and evaluation.

Yang Liu^1,2, Chen Yan^3,2, Borui Cao¹

¹State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China.

Biophysics Reports

|July 4, 2025

Summary

Researchers developed a drug-screening platform to find treatments for Charcot-Marie-Tooth disease type 2A (CMT2A). The platform identifies compounds that promote mitochondrial fusion and protect neurons, offering hope for this peripheral neuropathy.

Keywords:

CMT2A neuronal system Charcot-Marie-Tooth disease type 2A (CMT2A)Mitochondrial fusion Mitofusin-2 (MFN2)Screening and evaluation platform Small molecule compounds

More Related Videos

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Related Experiment Videos

Last Updated: Sep 17, 2025

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Simultaneous Measurement of Mitochondrial Calcium and Mitochondrial Membrane Potential in Live Cells by Fluorescent Microscopy

Published on: January 24, 2017

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

Area of Science:

Cell Biology
Neuroscience
Drug Discovery

Background:

Mitochondrial dynamics (fusion/fission) are vital for cellular functions, especially in the nervous system.
Mitofusin-2 (MFN2) mutations cause Charcot-Marie-Tooth disease type 2A (CMT2A), a peripheral neuropathy with no cure.
Previous work identified S89, a small molecule that promotes mitochondrial fusion and reduces axonal degeneration in CMT2A models.

Purpose of the Study:

To develop and validate a comprehensive drug-screening platform for identifying CMT2A therapeutics.
To leverage S89 as a benchmark compound within the screening platform.

Main Methods:

A three-stage screening platform was established: initial screening in Mfn knockout mouse embryonic fibroblasts (MEFs), followed by evaluation in CMT2A mouse primary neuronal cultures, and finally, assessment in patient-derived induced pluripotent stem cell (iPSC)-differentiated motor neurons.
The platform assesses mitochondrial fragmentation, morphology, axonal transport, and neurite outgrowth.

Main Results:

The developed platform enables rapid screening of compounds with increasing physiological relevance.
The platform is designed to enhance the efficiency and translational potential of identifying CMT2A therapeutic candidates.
S89 demonstrated efficacy in mitigating axonal degeneration in CMT2A models.

Conclusions:

The multi-tiered drug-screening platform is effective for identifying potential therapeutics for CMT2A.
This approach accelerates the discovery of treatments for peripheral neuropathies linked to mitochondrial dysfunction.
The platform holds promise for advancing therapeutic strategies for CMT2A and similar neurodegenerative diseases.